Aripiprazole (1,1,2,2,3,3,4,4-d8)
CAT:
804-HY-14546S1-01
Size:
500 µg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Aripiprazole (1,1,2,2,3,3,4,4-d8)
UNSPSC Description:
Aripiprazole (1,1,2,2,3,3,4,4-d8) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM[1][2].Target Antigen:
5-HT Receptor; Isotope-Labeled CompoundsType:
Isotope-Labeled CompoundsRelated Pathways:
GPCR/G Protein;Neuronal Signaling;OthersField of Research:
Neurological DiseaseSolubility:
10 mM in DMSOSmiles:
O=C1NC2=C(C=CC(OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])N3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=C2)CC1Molecular Weight:
456.43References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Stip E, Tourjman V. et al. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32 Suppl 1:S3-20.|[3]Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.|[4]Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.|[5]Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T. Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. Biopharm Drug Dispos. 2012 Jul 27. doi: 10.1002/bdd.1801.Shipping Conditions:
Room TemperatureClinical Information:
LaunchedCAS Number:
1089115-04-7